Angel News

Angel News

Back to Homepage

5th June 2020

Novo Ventures leads NodThera $55 million financing

NodThera, a clinical stage biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat diseases driven by chronic inflammation, has secured $55 million (£44 million) in a Series B financing. NodThera’s lead candidate, NT-0167, is being evaluated in a Phase 1 clinical trial in healthy volunteers.

...

Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:

Name:

Email:

Comment:

Enter the characters in the image shown:



Back to Homepage